Dr Karin Jooss | Chief Scientific Officer
Gritstone Oncology

Dr Karin Jooss, Chief Scientific Officer, Gritstone Oncology

Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology.  Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years.  While at Pfizer, she built and led immuno-oncology teams, was a member of the Vaccine Immunotherapeutics leadership team and served as the head of the Immunopharmacology team. Her duties included overseeing the assessment of all cancer vaccine in-licensing opportunities, and developing and launching Pfizer’s first clinical cancer vaccine program deploying a variety of vaccine platforms and immune modulators to build a multi-component vaccine-based immunotherapy regimen. Prior to joining Pfizer, Jooss served as vice president of Research at Cell Genesys, Inc. where she oversaw all research activities related to the company’s cancer vaccine and oncolytic virotherapy programs. Dr.Jooss received her Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania. She is on the editorial board of Molecular Therapy and Journal of Gene Medicine and is a member of the immunology and educational committee for the American Society of Gene Therapy as well as the Industry Task Force of the Society for Immunotherapy of Cancer (SITC).

Appearances:



Agenda Day 2 @ 2:15

Development of novel, personalized neoantigen immunotherapies

  • Using real time next-generation sequencing and bioinformatics approaches to identify and catalogue neoepitopes for each patient
  • How algorithms have increased the accuracy of identifying neoepitopes from 1% - 40%
  • Manufacture and delivery of personalized cancer vaccines either alone or in combination with other therapeutics

back to speakers